Rinri Therapeutics Limited

Rinri Therapeutics Ltd, based in Sheffield, UK, is a small, active company founded six years ago in 2018. It employs eleven people and holds £5,383,099 in assets. The company operates from a real address at The Innovation Centre and has six directors, although no owners are currently listed. It’s an irregular importer, primarily dealing in miscellaneous chemical products, with its last import activity recorded two months ago in May 2024.

The company’s website highlights its focus on regenerative cell therapy for hearing loss, positioning itself as a clinical-stage company developing innovative approaches to restore patient hearing. It emphasizes research and development, showcasing a portfolio of therapies and actively engaging with both clinicians and patients. The site includes videos demonstrating the technology and invites visitors to contact the company.

Financially, Rinri Therapeutics Ltd presents a mixed picture. Cash bank holdings have decreased by 13% to £4,900,000, while current assets have fallen 17% to £5,400,000. Creditors have doubled to £1,200,000, and net assets have declined by 35% to -£11,000,000—a substantial drop. Debtors have also significantly decreased, falling 42% to £480,000. The company’s small size (meeting two of three criteria for a small company) allows for flexibility, but the large equity decline suggests potential cash burn. The absence of an auditor mentioned likely means unaudited financial statements.

Despite these financial pressures, Rinri Therapeutics’ focus on a high-value, specialized area—regenerative medicine—could offer long-term growth potential. The company’s active engagement with the scientific community and patient network also suggests a strong foundation for future development.

Registered in England/Wales under the registration number 11680455, with a registered address at S1 4DP, Sheffield, South Yorkshire, The Innovation Centre 217 Portobello.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.